Johnson & Johnson’s Remicade (infliximab) scored highest for cost-effectiveness among the targeted immunomodulators on the market and in development for plaque psoriasis in a draft analysis released by the Institute for Clinical and Economic Review Sept. 29.
“Infliximab appears to be the most cost-effective targeted agent for psoriasis treatment, despite the necessity for intravenous administration,” ICER said....






